Hints and tips:
Related Special Reports
...living cells, such as Novo Nordisk’s Wegovy, which imitates a hormone called GLP-1....
...Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, plans to invest up to $7bn annually by 2030, as dividend payments from the maker of diabetes drug Ozempic and weight loss treatment...
...Investor excitement about Zealand comes as pharma groups seek to follow Novo Nordisk and Eli Lilly into the lucrative obesity market....
...But Jørgensen, the Novo Nordisk chief executive, viewed deepening its understanding of obesity as a way to see off the increasing competition....
...He said Novo Nordisk was facing a “similar challenge” as some of the companies selling advanced therapies....
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
...Novo Nordisk has struck a €1bn deal for a German biotech developing ribonucleic acid-based therapies to treat heart disease, as the Danish group invests the windfall from its best-selling diabetes and weight...
...A new study by Novo Nordisk has shown that its blockbuster drug Ozempic cut the risk of death, disease progression and cardiovascular issues by 24 per cent for patients with type 2 diabetes and chronic kidney...
...Novo Nordisk shares have hit a new record after the Danish drugmaker revealed early stage results for a new weight loss pill that offers better results than its blockbuster Wegovy....
...Novo Nordisk is the second-ever European company to achieve a $500bn market value following LVMH last April....
...But an oral pill may create its own supply problems, with a 50mg daily dose of Novo Nordisk’s semaglutide requiring 146 times as much active ingredient as a weekly injection, according to Barclays analysts...
...Novo Nordisk warned it would continue to face supply constraints in 2024 as it ramps up production of its Wegovy and Ozempic drugs to meet demand....
...It is controlled by a charity which has as its objectives the “stability” of Novo Nordisk, to support medical research and “other scientific, humanitarian and social purposes”....
...Ozempic” takes, referring to the diabetes and obesity medicine produced by Eli Lilly’s rival in the category, Novo Nordisk....
...Danish drugmaker Novo Nordisk has been “surprised” by the readiness of European consumers to pay for weight-loss drugs from their own pockets, as the region’s largest company invests in new supply to meet...
...Novo Nordisk shares hit a record high on Wednesday, as the Danish pharma group’s blockbuster weight-loss drugs powered a surge in sales and profits last year, cementing its position as Europe’s most valuable...
...As part of the transaction, Novo Holdings, which controls the majority of the Danish pharma group’s voting rights, has agreed to sell three of Catalent’s manufacturing sites to Novo Nordisk....
...In the race to develop a small molecule pill, Eli Lilly’s phase 3 orforglipron was “a bit of a frontrunner”, Novo Nordisk’s Lange acknowledged, but he said it was not as effective as injectables....
...Lilly relies on some of the sites to produce some of its own diabetes and obesity treatments, which compete with Novo Nordisk’s Ozempic and Wegovy, a class of drugs known as GLP-1s....
...As part of the deal announced on Monday, Novo Holdings will sell three of Catalent’s 50 sites to Novo Nordisk, after the company struggled to meet demand for its popular drugs, Ozempic and Wegovy....
...It also ensured Novo Nordisk was not for sale. “So not even Elon Musk in a wild night could take over or attempt to take over Novo Nordisk,” he says....
...Novo Nordisk’s competitors want to win a share of the market for diabetes and weight-loss drugs, which is forecast by Canadian investment bank BMO to grow to as much as $130bn to $140bn in annual sales....
...The results weighed on shares in Copenhagen-listed Novo Nordisk, which dipped as much as 5 per cent after the results before recovering to trade down 1.7 per cent....
...Novo Nordisk’s sales of obesity and diabetes drugs soared by 36 per cent to almost $22bn in the first nine months of the year, as patients flocked to treatments that offer more significant weight loss than...
...The US Food and Drug Administration says there is a shortage of Novo Nordisk’s and Eli Lilly’s diabetes drugs, while Belgium has banned the off-label use of Novo Nordisk’s diabetes drug for obesity treatments...
International Edition